

Resource Summary Report

Generated by [RRID](#) on Aug 30, 2026

SUM190PT

RRID:CVCL_3423

Type: Cell Line

Proper Citation

RRID:CVCL_3423

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3423

Proper Citation: RRID:CVCL_3423

Description: Cell line SUM190PT is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast inflammatory carcinoma

Defining Citation: [PMID:10424408](#), [PMID:10604729](#), [PMID:10969801](#), [PMID:15677628](#), [PMID:16397213](#), [PMID:16541312](#), [PMID:17157791](#), [PMID:19582160](#), [PMID:19593635](#), [PMID:23151021](#), [PMID:23401782](#), [PMID:23601657](#), [PMID:23784380](#), [PMID:24162158](#), [PMID:25877200](#), [PMID:28196595](#), [PMID:32715085](#), [PMID:35042871](#)

Comments: Characteristics: ER-negative, PR-negative and ERBB2-positive., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SUM190PT

Synonyms: SUM-190PT, SUM 190PT, SUM-190, SUM 190, SUM190, 190PT

Cross References: BTO:BTO_0005477, EFO:EFO_0001243, ArrayExpress:E-MTAB-11134, ArrayExpress:E-TABM-157, BioSample:SAMN03471033, cancercellines:CVCL_3423, Cosmic:904391, Cosmic:1046941, Cosmic:1287899, Cosmic:1289414, Cosmic:1460244, Cosmic:1603225, DepMap:ACH-001393, GEO:GSM217602, GEO:GSM350534, GEO:GSM847436, GEO:GSM847503, GEO:GSM1008918, GEO:GSM1053734, GEO:GSM1215269, GEO:GSM1238141,

IARC_TP53:24367, LINCS_HMS:51121, PharmacDB:SUM190_1511_2019, Progenetix:CVCL_3423, SLKBase:263, Wikidata:Q54970845

ID: CVCL_3423

Record Creation Time: 20220427T221612+0000

Record Last Update: 20260830T000037+0000

Ratings and Alerts

No rating or validation information has been found for SUM190PT.

No alerts have been found for SUM190PT.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Perurena N, et al. (2026) EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators. Cancer research, 86(6), 1467.

Rampa DR, et al. (2026) Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(8), 1454.

Mughees M, et al. (2025) Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers. Molecular cancer therapeutics, 24(9), 1453.

Watson SS, et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell systems, 6(3), 329.